• Advancing NAMs for in vitro Skin Sensitization Testing

    Top reasons customers test with us: Scientific Expertise and Personal Support

    Test with us - get a quote

GARD®skin: OECD 442E

Skin Sensitization Testing
Powered by Genomics and Machine Learning.
EXPLORE MORE

Do you have “difficult-to-test” samples?

UVCBs, Natural Extracts, Formulations and more.
LEARN MORE

Regulatory Toxicity Testing

GLP Compliant Laboratories

Medical Device Services

Biological Safety & Substance-Based Devices

Advisory Services

Toxicology, Pharmacology & Regulatory Compliance

Trusted by industry leaders

Who we work with – some highlights:

Cargill

Case study on Hydrophobic Esters

Joint poster at 2024 Eurotox

Corteva Agriscience

Case study on Agrochemical Formulations

Joint publication 2024 

ExxonMobil

Case study on UVCBs and Formulated Lubricant Products

Joint poster at 2023 SOT 

L’Oréal

Deriving a Point-of-Departure (PoD) from GARD® for Downstream Quantitative Risk Assessment

Joint publication 2024

Sonova

Integrating NAMs into Early-stage Screening of Novel Materials for Intended Use in Medical Devices

Joint poster at 2024 SOT

WHO WE WORK WITH

Join a thriving scientific community

– and never miss our latest webinars and insights

SIGN UP FOR UPDATES

Meet us

EVENT CALENDAR

Dr Andy Forreryd, Skin Sensitization Expert at SenzaGen, presenting at ESTIV about GARD®

Press Releases

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
13 Feb, 2025
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
GARD® going stronger and subsidiary enters new phase
06 Feb, 2025
News
IR
English
Corporate Information
Other Corporate Information
Invitation to the presentation of SenzaGen's year-end report 2024 on Feb 13 at 12.00
08 Nov, 2024
News
IR
English
Regulatory
MAR
Report
Interim
Q3
SenzaGen’s interim report January–September 2024: Strong quarter with over 30% growth
Next

News Posts

Subscribe


Prenumerera